Altis Biosystems, Inc.

Durham, NC · Founded 2018 · CIK 0001799892 · Medtech

RepliGut® StemScreen, a high-throughput plate-based assay platform for screening pharmaceutical effects on human GI stem cells

altisbiosystems.com →
Grants
$16M
19 awards
Sector median: 1
Raised
$4.4M
3 Form D · Apr 2025
18 months since last filing
Contracts
—
No federal contracts on record
Patents
2
0 granted · 2 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Co-culture cassette for anaerobes and primary human intestinal epithelium$224,898
Federal grantDepartment of Health and Human Services · Phase I · Developing a platform and optimized cell system for enteroendocrine cell-based assays and compound screening$223,049
Federal grantDepartment of Health and Human Services · Phase II · Co-culture cassette for anaerobes and primary human intestinal epithelium$1,493,382
Private capital raisedForm D · SEC$938,592
Federal grantDepartment of Health and Human Services · Phase I · Generating drug-screenable primary human intestinal epithelium by gene-editing and transgenesis$245,920
Federal grantDepartment of Health and Human Services · Phase II · Co-culture cassette for anaerobes and primary human intestinal epithelium$745,742
Federal grantDepartment of Health and Human Services · Phase II · Developing an optimized cell based platform for assays of the gastrointestinal enteroendocrine system$1,412,331
Federal grantDepartment of Health and Human Services · Phase II · Developing an optimized cell based platform for assays of the gastrointestinal enteroendocrine system$699,341
Federal grantDepartment of Health and Human Services · Phase I · A 2D Intestinal Crypt Platform for Compound Screens$256,543
Federal grantDepartment of Health and Human Services · Phase II · InflammaGut: a drug-screenable co-culture system using gut-associated lymphocytes and autologous primary human gut epithelium that reports inflammation$1,980,716
Federal grantDepartment of Health and Human Services · Phase I · A Mucus-producing Intestinal Epithelium Model for In Vitro Drug Absorption Testing$293,991
Federal grantDepartment of Health and Human Services · Phase I · Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk$256,574
Private capital raisedForm D · SEC$1,363,658
Federal grantDepartment of Health and Human Services · Phase II · A 2D Intestinal Crypt Platform for Compound Screens$1,888,698
Federal grantDepartment of Health and Human Services · Phase II · InflammaGut: a drug-screenable co-culture system using gut-associated lymphocytes and autologous primary human gut epithelium that reports inflammation$988,414
Federal grantDepartment of Health and Human Services · Phase II · Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk$913,659
Federal grantDepartment of Health and Human Services · Phase II · A 2D Intestinal Crypt Platform for Compound Screens$900,267
Federal grantDepartment of Health and Human Services · Phase I · MetabolGut: a rapid assay platform to evaluate the impact drugs on lipid-handlingpathways and chylomicron-associated drug distribution using stem cell-drivenhuman absorptive enterocytes.$343,297
Federal grantDepartment of Health and Human Services · Phase II · Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk$913,659
Private capital raisedForm D · SEC$2,126,307
Federal grantDepartment of Health and Human Services · Phase II · Mucus and ALI Models of the Human Intestine$835,939
Federal grantDepartment of Health and Human Services · Phase II · Mucus and ALI Models of the Human Intestine$1,001,183
Federal grant · SBIR/STTRForm D · SEC

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1081CRESCEL LLC—$1.4M
1082CALYX, INC.——
1083PROTEUS MOTION INC.—$16M
1084Altis Biosystems, Inc.—$4.4M
1085Orange Photonics, Inc.—$1.9M
1086DropletPharm Inc.——
1087EMANATE WIRELESS, INC.—$1.0M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 10 related persons
  • Michael BironDirector · Executive Officer
  • Kevin CauseyDirector
  • Michael DialDirector
  • Samuel FranklinDirector
  • Susan MahonyDirector
  • Joseph McMahonDirector
  • Christopher PerkinsDirector
  • Benjamin ScruggsDirector · Executive Officer
  • Christopher SimsDirector · Executive Officer
  • Jimmy SmedleyExecutive Officer

Patents

USPTO · 0 granted of 2
  • Cell Culture Systems Comprising Micropatterned Arrays And Methods Of Useapplication
  • Cell Culture Systems Comprising Micropatterned Arrays And Methods Of Useapplication

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.